Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by ...

The Tarrytown, New York-based company said it had profit of $12.81 per share. Earnings, adjusted for one-time gains and costs, were $12.89 per share. The results exceeded Wall Street expectations. The ...

To align with global demand and the company's planned maintenance, LYB expects third quarter operating rates of 85% for North ...

Alnylam Pharmaceuticals, Inc. shares soar with strong Q2 results, driven by Amvuttra's stellar U.S. launch for ATTR ...

Mediolanum International Funds Ltd has supercharged its investment in Regeneron Pharmaceuticals, increasing its stake by a ...

The second quarter of 2025 was a period of dynamic evolution within the biotech and pharma sectors. Critical factors like ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

The "Ophthalmics Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the report provides details of 344 ophthalmics ...

Regeneron Pharmaceuticals has recently launched a Phase 2 trial, testing the waters with a potential breakthrough in melanoma treatment. The trial explores the efficacy of fianlimab in tandem with ...

The Investment Canada Act (ICA) applies to all investments in Canada by non-Canadians. The Canadian government’s approach to investment reviews under the ICA has been shifting. While the review ...